NCT03700814

Brief Summary

This study assess whether there is any role of antibiotics to decrease wound infection and increase the success of surgery

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Jan 2014

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 10, 2014

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 6, 2015

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2015

Completed
3.1 years until next milestone

First Submitted

Initial submission to the registry

September 29, 2018

Completed
10 days until next milestone

First Posted

Study publicly available on registry

October 9, 2018

Completed
Last Updated

October 10, 2018

Status Verified

October 1, 2018

Enrollment Period

1.4 years

First QC Date

September 29, 2018

Last Update Submit

October 8, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • : Number of Participants with postoperative wound infection

    Number of participants who have had at least one episode of infection in the postoperative period. postoperative infection : Infection occurring within 4 weeks of postoperative periods Postoperative infection : Presence of any of the following findings on clinical examination 1. Wound gaping 2. Purulent discharge from incision site 3. Purulent discharge from external auditory canal Measurement tool used to assess the measure * Clinical examination of patient by examiner * Wound assessment : Examination of pinna , incision site and graft donor site * Any signs of infections if present will be noted in performa.

    At Visit 1, [Post-op Day 1 ], at Visit 2 [Post-op Day 3] ,at Visit 3 [Day 8 to Day 14] ], at Visit 4 [ Day 28 to day 30]

Secondary Outcomes (1)

  • Number of Participants with successful graft uptake

    At Visit 4 [ Day 28 to day 30], at Visit 5 [ day 80 to day 90]

Study Arms (2)

Antibiotics group

EXPERIMENTAL

Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which will be injected 30 minutes prior to the incision during surgery.

Drug: Co-amoxiclav

No antibiotics group

NO INTERVENTION

Patients belonging to this group will not receive any systemic antibiotic during intraoperative or post-operative period.

Interventions

Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which was injected 30 minutes prior to the incision during surgery.

Antibiotics group

Eligibility Criteria

Age6 Years - 15 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Age : patients between 6 to 15 years of age
  • Gender : both male and female patients
  • Disease: Chronic otitis media mucosal inactive (dry for at least 4 weeks)

You may not qualify if:

  • Actively discharging ear pre-operatively
  • Revision myringoplasty
  • Allergic to co-amoxiclav

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Khanal P, Guragain RP, Bhusal CL. Comparison of postoperative infection and graft uptake rate using single dose of intravenous co-amoxiclav versus no antibiotic in children undergoing myringoplasty: A randomized controlled trial. Int J Pediatr Otorhinolaryngol. 2020 Apr;131:109893. doi: 10.1016/j.ijporl.2020.109893. Epub 2020 Jan 18.

MeSH Terms

Conditions

Surgical Wound Infection

Interventions

Amoxicillin-Potassium Clavulanate Combination

Condition Hierarchy (Ancestors)

Wound InfectionInfectionsPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Clavulanic AcidClavulanic Acidsbeta-LactamsLactamsAmidesOrganic ChemicalsAmoxicillinAmpicillinPenicillin GPenicillinsSulfur CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsDrug CombinationsPharmaceutical Preparations

Study Officials

  • Prakash Khanal, MS,ENT

    Ganesh Man Singh Memorial Academy (GMSMA) of ENT-Head and Neck Studies, TU Teaching Hospital, Institute of Medicine (IOM)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
ENT- Head and Neck Surgeon

Study Record Dates

First Submitted

September 29, 2018

First Posted

October 9, 2018

Study Start

January 10, 2014

Primary Completion

June 6, 2015

Study Completion

September 1, 2015

Last Updated

October 10, 2018

Record last verified: 2018-10